Advanced Scientific Insights.
100% U.S. Operations.
One partner for all your sequencing needs. Partner with a CLIA-certified and CAP-accredited CRO that prioritizes your data security and expertise for your most critical research projects.
Everything happens here.
Admera makes outsourced sequencing seamless and secure. Every step of our operation is performed at our facility in South Plainfield, New Jersey, ensuring transparent workflows, streamlined operations, and reliable service from start to finish. Your data never leaves US soil.
Offering rapid turnaround times and competitive pricing, Admera partners with you as an extension of your laboratory. Our CAP/CLIA-certified facility ensures every sample is handled with rigor, care, and consistent quality.
Admera Health, LLC is a U.S. company, headquartered in New Jersey, with all governance, management, and operations in the United States.
Founded in 2012, we are a CLIA-certified and CAP-accredited next-generation sequencing (NGS) contract research organization (CRO) that offers genome sequencing, exome sequencing, RNA sequencing, single-cell RNA sequencing, spatial transcriptomics, as well as other sequencing and bioinformatics services.
126 Corporate Blvd,
South Plainfield NJ 08820
(908)-222-0533
[email protected]
Address & Contact Info
What Researchers Can Expect When Working With Us
Workflow Transparency & Security
Clear communication from your designated project manager with dedicated project oversight
Exceptional Quality
Admera is a CAP accredited, CLIA-certified laboratory, upholding the highest laboratory quality standards
Competitive Pricing & Cost Efficiency
High-quality sequencing without hidden costs
Rapid Turnaround Times
Optimized workflows are designed to keep your research moving
What Our Customers Say
"Admera Health has been a great partner for us. In our work on AI drug research and discovery, we need high-quality data quickly, and Admera has continuously delivered.
Their single-cell sequencing projects have played a big role in helping us build a large single-cell dataset. This has been a key part of moving our pipeline forward and training our AI models for virtual cell platforms.
Their collaborative team works closely with us to make sure the data they deliver is the right fit for what we need. This partnership has helped us to scale our efforts with confidence. With their support, we’ve been able to speed up our research and development timeline and explore thousands of drug-patient interactions.
We value the work and support from the Admera team and look forward to continuing the collaboration."
-Johnny Yu, CEO, Tahoe Therapeutics (Formerly Vevo)
“Our group recently transitioned from in-house sequencing to outsources, an the experience has been seamless. We greatly value their quick turnaround time. Their flexibility in accommodating our specific needs and workflows has been invaluable, making the adjustment from in-house operations effortless.
On top of that, their highly competitive pricing has made the switch not only easy, but also a financially attractive decision. Partnering with Admera has been a game-changer for our sequencing needs, and we couldn’t be more pleased with their exceptional service.”
-Artificial Intelligence (AI) Drug Discovery Biotech
“We are a functional genomics lab at Duke University that generates both standard and in-house designed NGS libraries, often built on our newly developed technologies and protocols. Sequencing these libraries often requires tailored NGS strategies, and finding the right NGS provider used to be a challenge - until we partnered with Admera Health.
Their expertise in NGS is truly outstanding, covering multiple commercial NGS platforms and the latest technologies. Their deep scientific and technical knowledge allows us to have productive discussions to optimize our sequencing approaches at no extra cost. The turnaround time is also remarkable - often just three days over over a weekend - and their pricing is highly competitive. Admera has exceeded our expectations, and we always recommend their services to collaborators. We look forward to continuing our partnership in the future.”
-Associate Professor, Department of Cell Biology, Duke University
Featured Publications
A 3D Tumor Spheroid Model with Robust T Cell Infiltration for Evaluating Immune Cell Engagers
This post is for informational purposes only and is not an endorsement of Admera Health by AbbVie or the publication's authors.
Generation of Functional Human 3D Cortico-Motor Assembloids
This post is for informational purposes only and is not an endorsement of Admera Health by Stanford or the publication's authors.
Time-series sewage metagenomics distinguishes seasonal, human-derived and environmental microbial communities potentially allowing source attributed surveillance
This post is for informational purposes only and is not an endorsement of Admera Health by DTU or the publication's authors.
Single-cell transcriptomic landscape of the developing human spinal cord
This post is for informational purposes only and is not an endorsement of Admera Health by Stanford or the publication's authors.
See our suite of sequencers and multiomics platforms available in our lab. From pre-made library sequencing to full-service library preparation, we utilize advanced tools to make high-throughput, high-accuracy data generation seamless, scalable, and project-ready.